|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108.
2005.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Park MS, Lee KW, Yi NJ, Choi YR, Kim H,
Hong G, Suh KS, Kwon CH, Joh JW and Lee SK: Optimal tailored
screening protocol after living donor liver transplantation for
hepatocellular carcinoma. J Korean Med Sci. 29:1360–1366.
2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Mukherjee S and Mukherjee U: A
comprehensive review of immunosuppression used for liver
transplantation. J Transplant. 2009(701464)2009.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Moini M, Schilsky ML and Tichy EM: Review
on immunosuppression in liver transplantation. World J Hepatol.
7:1355–1368. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Liu Z, Chen Y, Tao R, Xv J, Meng J and
Yong X: Tacrolimus-based versus cyclosporine-based
immunosuppression in hepatitis C virus-infected patients after
liver transplantation: A meta-analysis and systematic review. PLoS
One. 9(e107057)2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Rodríguez-Perálvarez M, De la Mata M and
Burroughs AK: Liver transplantation: Immunosuppression and
oncology. Curr Opin Organ Transplant. 19:253–260. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Chen K, Man K, Metselaar HJ, Janssen HL,
Peppelenbosch MP and Pan Q: Rationale of personalized
immunosuppressive medication for hepatocellular carcinoma patients
after liver transplantation. Liver Transpl. 20:261–269.
2014.PubMed/NCBI View
Article : Google Scholar
|
|
9
|
Lee KW, Seo YD, Oh SC, Suh SW, Jeong J,
Kim H, Yi NJ and Suh KS: What is the best immunosuppressant
combination in terms of antitumor effect in hepatocellular
carcinoma? Hepatol Res. 46:593–600. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Menon KV, Hakeem AR and Heaton ND:
Meta-analysis: Recurrence and survival following the use of
sirolimus in liver transplantation for hepatocellular carcinoma.
Aliment Pharm Ther. 37:411–419. 2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Jeng LB, Thorat A, Hsieh YW, Yang HR, Yeh
CC, Chen TH, Hsu SC and Hsu CH: Experience of using everolimus in
the early stage of living donor liver transplantation. Transplant
Proc. 46:744–748. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Finn RS: Current and future treatment
strategies for patients with advanced hepatocellular carcinoma:
Role of mTOR inhibition. Liver Cancer. 1:247–256. 2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Yin S, Li J, Hu C, Chen X, Yao M, Yan M,
Jiang G, Ge C, Xie H, Wan D, et al: CD133 positive hepatocellular
carcinoma cells possess high capacity for tumorigenicity. Int J
Cancer. 120:1444–1450. 2007.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Suetsugu A, Osawa Y, Nagaki M, Moriwaki H,
Saji S, Bouvet M and Hoffman RM: Simultaneous color-coded imaging
to distinguish cancer ‘stem-like’ and non-stem cells in the same
tumor. J Cell Biochem. 111:1035–1041. 2010.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO,
Zheng BJ and Guan XY: Identification and characterization of
tumorigenic liver cancer stem/progenitor cells. Gastroenterology.
132:2542–2556. 2007.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001.PubMed/NCBI View
Article : Google Scholar
|
|
17
|
Kumar P, Nagarajan A and Uchil PD:
Analysis of cell viability by the MTT assay. Cold Spring Harb
Protoc 2018, 2018.
|
|
18
|
Mussin N, Oh SC, Lee KW, Park MY, Seo S,
Yi NJ, Kim H, Yoon KC, Ahn SW, Kim HS, et al: Sirolimus and
metformin synergistically inhibits colon cancer in vitro and in
vivo. J Korean Med Sci. 32:1385–1395. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Hui IC, Tung EK, Sze KM, Ching YP and Ng
IO: Rapamycin and CCI-779 inhibit the mammalian target of rapamycin
signalling in hepatocellular carcinoma. Liver International.
30:65–75. 2010.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ji J and Wang XW: Clinical implications of
cancer stem cell biology in hepatocellular carcinoma. Semin Oncol.
39:461–472. 2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Sgourakis G and Dedemadi G:
Corticosteroid-free immunosuppression in liver transplantation: An
evidence-based review. World J Gastroenterol. 20:10703–10714.
2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Turner AP and Knechtle SJ: Induction
immunosuppression in liver transplantation: A review. Transpl Int.
26:673–683. 2013.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Vivarelli M, Dazzi A, Cucchetti A,
Gasbarrini A, Zanello M, Di Gioia P, Bianchi G, Tamè MR, Gaudio MD,
Ravaioli M, et al: Sirolimus in liver transplant recipients: A
large single-center experience. Transplant Proc. 42:2579–2584.
2010.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Thorat A, Jeng LB, Yang HR, Yeh CC, Hsu
SC, Chen TH and Poon KS: Assessing the role of everolimus in
reducing hepatocellular carcinoma recurrence after living donor
liver transplantation for patients within the UCSF criteria:
Re-inventing the role of mammalian target of rapamycin inhibitors.
Ann Hepatobiliary Pancreat Surg. 21:205–211. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Geissler EK, Schnitzbauer AA, Schlitt HJ
and Si LSG: Lack of benefits of mammalian target of rapamycin
inhibitor in patients transplanted for hepatocellular carcinoma: Is
this the end of the story? Liver Transpl. 22:1162–1163.
2016.PubMed/NCBI View
Article : Google Scholar
|
|
26
|
Yamashita T, Ji J, Budhu A, Forgues M,
Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, et al:
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating
cells with stem/progenitor cell features. Gastroenterology.
136:1012–1024. 2009.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Na DC, Lee JE, Yoo JE, Oh BK, Choi GH and
Park YN: Invasion and EMT-associated genes are up-regulated in B
viral hepatocellular carcinoma with high expression of CD133-human
and cell culture study. Exp Mol Pathol. 90:66–73. 2011.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J and
Li J: Cancer stem/progenitor cells are highly enriched in
CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer.
126:2067–2078. 2010.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Winter MJ, Nagelkerken B, Mertens AE,
Rees-Bakker HA, Briaire-de Bruijn IH and Litvinov SV: Expression of
Ep-CAM shifts the state of cadherin-mediated adhesions from strong
to weak. Exp Cell Res. 285:50–58. 2003.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Kim JW, Ye QH, Forgues M, Chen YD, Budhu
A, Sime J, Hofseth LJ, Kaul R and Wang XW: Cancer-associated
molecular signature in the tissue samples of patients with
cirrhosis. Hepatology. 39:518–527. 2004.PubMed/NCBI View Article : Google Scholar
|
|
31
|
de Boer CJ, Van Krieken JH, Janssen-Van
Rhijn CM and Litvinov SV: Expression of Ep-CAM in normal,
regenerating, metaplastic, and neoplastic liver. J Pathol.
188:201–206. 1999.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Ruck P, Wichert G, Handgretinger R and
Kaiserling E: Ep-CAM in malignant liver tumours. Journal of
Pathology. 191:102–103. 2000.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Luo J, Wang P, Wang R, Wang J, Liu M,
Xiong S, Li Y and Cheng B: The Notch pathway promotes the cancer
stem cell characteristics of CD90+ cells in hepatocellular
carcinoma. Oncotarget. 7:9525–9537. 2016.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Yang Z, Zhang L, Ma A, Liu L, Li J, Gu J
and Liu Y: Transient mTOR inhibition facilitates continuous growth
of liver tumors by modulating the maintenance of CD133+ cell
populations. PLoS One. 6(e28405)2011.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Matsumoto K, Arao T, Tanaka K, Kaneda H,
Kudo K, Fujita Y, Tamura D, Aomatsu K, Tamura T, Yamada Y, et al:
mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133
expression in cancer cells. Cancer Res. 69:7160–7164.
2009.PubMed/NCBI View Article : Google Scholar
|
